Completed PHASE1 INTERVENTIONAL 4-arm NCT04045769

A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

Sponsor: Zydus Therapeutics Inc.

Conditions Healthy

Interventions Moxifloxacin 400mg Placebos Saroglitazar magnesium 20 mg Saroglitazar magnesium 4mg

Updated 6 times since 2019 Last updated: Apr 20, 2020 Started: Aug 19, 2019 Primary completion: Nov 27, 2019 Completion: Dec 2, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04045769, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Zydus Therapeutics Inc., it has been updated 6 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Oct 2021 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Sep 2019 — May 2020 [monthly]

Recruiting PHASE1

First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zydus Therapeutics Inc.

Data source: Zydus Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ahmedabad, India